<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01859897</url>
  </required_header>
  <id_info>
    <org_study_id>okayama-1692</org_study_id>
    <nct_id>NCT01859897</nct_id>
  </id_info>
  <brief_title>A Prospective Multicenter Study to Evaluate Usefulness of Cardio-Ankle Vascular Index in Japan</brief_title>
  <acronym>CAVI-J</acronym>
  <official_title>A Prospective Multicenter Study to Evaluate Usefulness of Cardio-Ankle Vascular Index in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAVI-J Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Toho University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ehime University Graduate School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dokkyo Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Okayama University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Okayama University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this five-year prospective observational follow-up study is to examine the&#xD;
      additional benefits of using cardio-ankle vascular index (CAVI) as a predictive indicator of&#xD;
      cardiovascular events in high-risk patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Actual">April 2020</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>major cardiac events</measure>
    <time_frame>five years</time_frame>
    <description>cardiac death, nonfatal myocardial infarction, stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all cause mortality, cardiovascular events, and renaly dysfunction</measure>
    <time_frame>five years</time_frame>
    <description>all cause death, angina pectoris (with revascularization), New incidence of lower limb peripheral arterial disease(including lower limb arteriosclerosis obliterans), Aortic aneurysm, Aortic dissection, Heart failure that requires hospitalization, Deterioration in renal function (dialysis or renal transplantation)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in CAVI and cardiovascular events</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3026</enrollment>
  <condition>Stroke</condition>
  <condition>Cardiovascular Death</condition>
  <condition>Nonfatal Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Optimal therapy</arm_group_label>
    <description>All subjects will be treated by optimal medical therapy and lifestyle modification.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        primiary care clinic and hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients between 40 and 74 years of age who have either of the following:&#xD;
&#xD;
          1. Type 2 diabetes mellitus&#xD;
&#xD;
          2. Metabolic syndrome&#xD;
&#xD;
          3. Grade I to III hypertension with the third layer of risk factors according to the&#xD;
             guidelines for the management of hypertension japanese society of&#xD;
             hypertension(JSH)2009&#xD;
&#xD;
          4. Chronic kidney disease(stage G3a or G3b) according ot the clinical Practice Guidebook&#xD;
             for Diagnosis and Treatment of Chronic Kidney Disease 2012 in Japan&#xD;
&#xD;
          5. History of coronary artery disease or noncardiogenic cerebral infarction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Under 40 years of age or over 74 years of age&#xD;
&#xD;
          2. An ankle-brachial index less than 0.9&#xD;
&#xD;
          3. Chronic atrial fibrillation&#xD;
&#xD;
          4. Current symptoms of heart failure(NYHA class III or IV) or left ventricular&#xD;
             dysfunction (EF below 40%)&#xD;
&#xD;
          5. Malignancy&#xD;
&#xD;
          6. Chronic kidney disease(G4 or G5)according ot the clinical Practice Guidebook for&#xD;
             Diagnosis and Treatment of Chronic Kidney Disease 2012 in Japan&#xD;
&#xD;
          7. chronic dialysis due to renal failure&#xD;
&#xD;
          8. Taking steroids/immunosuppressants&#xD;
&#xD;
          9. Hepatocirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hajime Orimo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenkoin Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Okayama University</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.cavij.com/</url>
    <description>Click here for more information about this study (in Japanese)</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>May 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Okayama University</investigator_affiliation>
    <investigator_full_name>CAVI-J Study Group</investigator_full_name>
    <investigator_title>CAVI-J study Group</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

